gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · XNCRHealthcarePharmaceuticals

Xencor, Inc. (XNCR)

$35.03+14.33%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$35.03▲ 155.69% in range
Nov 4, 2025Low $10.41 · High $35.03Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Xencor closed at $35.03 on Nov 4, up 14.33% — matching its 52-week closing high. Volume of 2.5M shares was 1.40× its 20-day average (above normal).

Split-adjusted performance: +43.8% over one month, +169.3% over six months, +151.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $51.22M, up 17.5% from a year earlier, with a net margin of -42.4%.

Short interest was 12.3M shares at the Oct 15 settlement, down 25.1% from the prior report (17.0% of float, 9.1 days to cover).

Market cap$2.60B74.4M shares
Revenue · quarter$51.2M+17.5% YoY
Diluted EPS$-0.29—
P/E · TTM—P/S 24.8×
Net margin-42.4%Gross 100.0%
Dividend yieldNone
52-week range10.41 – 35.030.0% from high
Volume2.5M1.40× 20-day avg
Volatility · 60d67.2%Annualised
Short % of float17.0%9.1 days to cover
Net cash$351.6MCash $456.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +16.8%1M +43.8%3M +75.2%6M +169.3%YTD +128.8%1Y +151.3%3Y +103.3%5Y −10.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum100
Revenue growth64
Net margin47
Value (low P/E)—
Size85

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short12.3M−25.1% vs prior
Days to cover9.1Settled Oct 15
% of float17.0%
Short vol. 10d71.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
XNCRXencor$35.03+14.33%+169.3%+17.5%−42.4%—$2.60B
MBXMBX Biosciences$52.48−4.58%+63.4%———$2.53BCompare
PBHPrestige Consumer Healthcare$53.28+7.55%−1.9%+6.5%11.0%14.7$2.52BCompare
NAMSNewAmsterdam Pharma Company N.V$20.93+5.18%−32.5%−80.7%−1732.9%—$2.50BCompare
RCUSArcus Biosciences$19.31+2.12%−25.7%−74.4%−222.0%—$2.46BCompare
PVLAPalvella Therapeutics$162.28+6.11%+24.7%———$2.34BCompare
VERAVera Therapeutics$31.97+4.10%−12.6%———$2.30BCompare
IMNMImmunome$19.52−3.89%−16.1%−100.0%——$2.30BCompare
BHVNBiohaven$15.24−2.37%+51.8%———$2.30BCompare

News about Xencor

All news →
Xencor (XNCR) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research · 10h ago▼ Negative

Quick answers

What does Xencor do?
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates.
What is XNCR's market cap?
$2.60B, based on the Nov 4 close of $35.03.
Does Xencor pay a dividend?
No regular cash dividend has been paid in the last year.
How much of XNCR is sold short?
12.3M shares, 17.0% of float, as of Oct 15, 2026.
What sector is XNCR in?
Healthcare, in the Pharmaceuticals industry.

About Xencor

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

HQ: Pasadena, CA260 employeesListed Dec 3, 2013xencor.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology